Iovance Biotherapeutics, Inc. Common Stock

IOVA Real Time Price USD
1.69
-0.03
(-1.72%)
As of today at 04:52 UTC-04:00 (Market Closed)
Add to Watchlist
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of IOVA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
IOVA Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
IOVA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
IOVA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Whales114.3333333New52Increased96Held50Decreased91Closed54
Insider Trading

Quarterly net insider trading by IOVA's directors and management

2024Q32024Q42025Q12025Q2−40k−20k020k40k
Net Shares Purchased by Insiders
Corporate Lobbying

Government lobbying spending instances

  • $260,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $260,000 Oct 11, 2022 Issue: Medicare/Medicaid Health Issues
  • $260,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $50,000 Apr 20, 2022 Issue: Medicare/Medicaid
  • $50,000 Apr 19, 2022 Issue: Health Issues
  • $50,000 Jan 20, 2022 Issue: Health Issues
  • $50,000 Jan 19, 2022 Issue: Medicare/Medicaid
  • $50,000 Oct 20, 2021 Issue: Medicare/Medicaid
  • $50,000 Oct 20, 2021 Issue: Health Issues
  • $50,000 Jul 20, 2021 Issue: Medicare/Medicaid
  • $50,000 Jul 19, 2021 Issue: Health Issues
  • $40,000 Apr 20, 2021 Issue: Medicare/Medicaid
  • $40,000 Apr 19, 2021 Issue: Health Issues
  • $30,000 Jan 21, 2021 Issue: Medicare/Medicaid
  • $30,000 Jan 19, 2021 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

202120220200k400k600k800k
Q4Q3Q2Q1Lobbying Amount
Revenue Breakdown

IOVA Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
IOVA Income Statement
IOVA Balance Sheet
IOVA Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Feb. 25, 2025
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Feb. 18, 2025
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Feb. 18, 2025
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 18, 2025
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 14, 2025
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 07, 2025
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Dec. 17, 2024
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Dec. 03, 2024
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Oct. 22, 2024
  • Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Oct. 01, 2024
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 09, 2024
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 02, 2024
  • Patent Title: Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof Jul. 02, 2024
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jun. 04, 2024
  • Patent Title: Til expansion processes using specific cytokine combinations and/or akti treatment May. 14, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 07, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 30, 2024
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 26, 2024
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 09, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 09, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 02, 2024
  • Patent Title: Methods of using tumor infiltrating lymphocytes in double-refractory melanoma Nov. 21, 2023
  • Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Aug. 01, 2023
  • Patent Title: Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion Jun. 06, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 16, 2023
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Apr. 18, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 03, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 20, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 06, 2022
  • Patent Title: Methods of using tumor infiltrating lymphocytes in double-refractory melanoma Sep. 06, 2022
  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Aug. 02, 2022
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 12, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 28, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 21, 2022
  • Patent Title: Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof Jun. 14, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 07, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 07, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 31, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 31, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 31, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 24, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 26, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 19, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 19, 2022
  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Apr. 05, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 05, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 15, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 15, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Mar. 08, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 22, 2022
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

20242025050k100k150k200k
Q4Q3Q2Q1Government Contracts Amount
IOVA News

Recent insights relating to IOVA

Iovance Biotherapeutics Announces Upcoming Presentation at Goldman Sachs Global Healthcare Conference6/10/2025, 12:56:15 PMArticle Thumbnail
Insider Purchase: Chief Commercial Officer of $IOVA Buys 30,000 Shares6/6/2025, 8:17:45 PMArticle Thumbnail
New Insider Disclosure: Kirby Daniel Gordon (Chief Commercial Officer) disclosed 30000 shares bought of $IOVA6/6/2025, 8:17:00 PMArticle Thumbnail
Iovance Biotherapeutics Reports Five-Year Results of Amtagvi Treatment Showing Sustained Responses and Survival in Advanced Melanoma Patients6/2/2025, 1:40:42 PMArticle Thumbnail
New Insider Disclosure: Puri Raj K. (Chief Regulatory Officer) disclosed 5600 shares bought of $IOVA5/27/2025, 8:17:00 PMArticle Thumbnail
Iovance Biotherapeutics Reports Five-Year Results of Amtagvi Treatment for Advanced Melanoma, Highlighting 20% Overall Survival Rate5/22/2025, 9:41:22 PMArticle Thumbnail
New Analyst Forecast: $IOVA Given $2.0 Price Target5/19/2025, 10:21:38 AMArticle Thumbnail
Iovance Biotherapeutics, Inc. to Report First Quarter 2025 Financial Results and Corporate Updates on May 8, 20255/2/2025, 8:14:10 PMArticle Thumbnail
$IOVA stock is up 7% today. Here's what we see in our data.4/25/2025, 3:30:56 PMArticle Thumbnail
Iovance Biotherapeutics to Present Pre-Clinical and Five-Year Outcomes Data at 2025 AACR and ASCO Annual Meetings4/23/2025, 8:25:18 PMArticle Thumbnail
Iovance Biotherapeutics Grants Inducement Stock Options to Fifty New Employees4/18/2025, 9:40:17 PMArticle Thumbnail
Iovance Biotherapeutics Grants Inducement Stock Options and Restricted Stock Units to New Chief Commercial Officer2/12/2025, 10:40:56 PMArticle Thumbnail
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer to Drive Growth of Amtagvi and Proleukin2/10/2025, 12:13:39 PMArticle Thumbnail
New Lobbying Disclosure: IOVANCE BIOTHERAPEUTICS, INC. ($IOVA) disclosed spending $170000 lobbying (General Medicare / Medicaid Reimbursement.)3/14/2023, 10:00:00 PMArticle Thumbnail
New Lobbying Disclosure: IOVANCE BIOTHERAPEUTICS, INC. ($IOVA) disclosed spending $260000 lobbying (General Medicare / Medicaid Reimbursement. )1/20/2023, 2:18:00 PMArticle Thumbnail
New Lobbying Disclosure: IOVANCE BIOTHERAPEUTICS, INC. ($IOVA) disclosed spending $50000 lobbying (Education around tumor infiltrating lymphocytes (TIL) cancer therapies; S. 3700/H.R. 6833, Affordable Insulin Now Act; Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation; Issues related to the Public Health Emergency; Issues related to the White House Cancer Moonshot initiative; Issues related to accelerated approval; CMS Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) Rates Proposed Rule for FY 2023; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act; Executive Order Directing HHS to Explore Additional Actions to Lower Prescription Drug Costs)1/20/2023, 1:17:00 PMArticle Thumbnail
New Lobbying Disclosure: IOVANCE BIOTHERAPEUTICS, INC. ($IOVA) disclosed spending $50000 lobbying (FY 2022 IPPS Rule as it relates to cell therapies. )1/19/2023, 8:10:00 PMArticle Thumbnail
CNBC Recommendations

Recent picks made for IOVA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in IOVA

IOVA Analyst Ratings

IOVA Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
IOVA Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $IOVA stock a Buy, Sell, or Hold?

  • What is the price target for $IOVA stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

IOVA Top Shareholders
Shareholder
Shares Held
IOVA Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $IOVA stock?

  • Who owns the most shares of $IOVA stock?

  • What funds own $IOVA stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

IOVA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view IOVA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Bull Case vs Bear Case data is only available to Quiver Premium subscribers.

Back To Top